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Abstract
Introduction—Little is known about the effect of breast cancers on health-related quality of life 
among women diagnosed between age 18 and 44 years. The goal of this study is to estimate the 
effect of breast cancer on health state utility by age at diagnosis (18–44 years versus ≥45 years) 
and by race/ethnicity.
Methods—The analytic sample, drawn from the 2009 and 2010 Behavioral Risk Factor 
Surveillance System and analyzed in 2013, included women diagnosed with breast cancer between 
age 18 and 44 years (n=1,389) and age ≥45 years (n=6,037). Health state utility values were 
estimated using Healthy Days variables and a published algorithm. Regression analysis was 
conducted separately by age at diagnosis and race/ethnicity.
Results—The breast cancer health state utility decrement within 1 year from date of diagnosis 
was larger for women diagnosed at age 18–44 years than for women diagnosed at age ≥45 years 
(−0.116 vs −0.070, p<0.05). Within the younger age-at-diagnosis group, Hispanic women 2–4 
years after diagnosis had the largest health state utility decrement (−0.221, p<0.01), followed by 
non-Hispanic white women within 1 year of diagnosis (−0.126, p<0.01).
Conclusions—This study is the first to report estimates of health state utility values for breast 
cancer by age at diagnosis and race/ethnicity from a nationwide sample. The results highlight the 
need for separate quality of life adjustments for women by age at diagnosis and race/ethnicity 
when conducting cost-effectiveness analysis of breast cancer prevention, detection, and treatment.
Introduction
Approximately 12% of new breast cancer cases occur in women younger than age 45 years.1 
Unlike for older women, the incidence of breast cancer with distant involvement (metastatic 
breast cancer) among younger women has increased significantly over the past 30 years.2 
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Breast cancer negatively affects women’s health-related quality of life (HRQoL), potentially 
more for younger women.3–16 Younger women with breast cancer commonly face 
chemotherapy-induced menopause, decreased sexual function, infertility, diminished body 
image, and other side effects.15–18 Owing to more-aggressive and less responsive tumors,
12,19
 breast cancer diagnosed at a younger age is also correlated with lower survival rates, 
higher recurrence rates, and negative prognostic variables.19–21
The HRQoL decrement attributable to breast cancer also varies by race/ethnicity. Hispanic 
breast cancer survivors report significantly lower HRQoL for all domains (mental, 
emotional, and physical) than any other racial/ethnic group,22–24 although differences are 
only significant among women older than age 50 years.14 Results for black women with 
breast cancer have been mixed, with some studies reporting low physical functioning among 
black women,25 and others reporting better emotional well-being and mental health 
compared with non-Hispanic white women.14,23 To the authors’ knowledge, the way in 
which racial/ethnic differences in HRQoL vary by age at diagnosis has not been explored in 
the literature.
Most HRQoL measures for breast cancer survivors use condition-specific instruments.26 
Alternative instruments, such as the EuroQoL five-dimensions (EQ-5D) (www.euroqol.org/), 
capture broad measures of health-related well-being. Preference-based HRQoL measures 
elicit patient preferences over health states through visual analog scales, time trade-offs, and 
standard gambles.27 These choices are represented as preference-based health state utility 
(HSU) values, which are scaled to a single 0 (dead) to 1 (best health) cardinal index.28 HSU 
is a special HRQoL measure that represents global health-related well-being, is based on 
preference-based tradeoffs, and is used in economic evaluations to value improvements in 
morbidity and mortality from interventions (e.g., quality-adjusted life-years). The goal of 
this study is to estimate the effect of breast cancer on HSU by age at diagnosis (18–44 years 
versus ≥45 years) and by race/ethnicity. This study is the first to measure the impact of 
breast cancer on HSUs based on a preference-based measure of HRQoL by age at diagnosis 
and race/ethnicity from a population-based national sample.
Methods
Data
The Behavioral Risk Factor Surveillance System (BRFSS) is an annual, state-based, 
telephone health survey of non-institutionalized adults supported by CDC. The BRFSS 
sample is drawn from each U.S. state and some territories using random-digit-dial sampling 
methods.29 In 2009, four cancer survivorship questions were asked in all states. In 2010, a 
total of 13 states and territories (i.e., Alaska, California, Colorado, Connecticut, Indiana, 
Massachusetts, Missouri, New Mexico, Ohio, Oklahoma, South Dakota, Wisconsin, and 
Guam) asked the cancer survivorship questions in an optional cancer survivorship module. 
The BRFSS cancer survivorship questions measure whether an individual has ever been 
diagnosed with cancer, type of cancer, age at which cancer was diagnosed, and the number 
of cancers previously diagnosed.29 The authors pooled the 2009 data for all states and 
territories and the 2010 data for the 13 states and territories listed above to maximize 
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available sample size. The median response rate for the entire BRFSS across included states 
was 52% in 2009 and 58% in 2010.
Measures
The BRFSS core module measures population HRQoL using the Healthy Days (HRQoL-4) 
module.29 This study focused on two questions that asked how many days in the past 30 the 
respondent’s health was not good—one question for physical health and another question for 
mental health. Two questions were used to define “overall healthy days” as 30 – (physically 
unhealthy days) – (mentally unhealthy days), with values <0 set to 0. This “overall healthy 
days” measure was then mapped, using estimates from the literature, to HSU (described 
below).
A binary variable was generated to indicate if a respondent has ever had breast cancer. 
Because respondents were asked to report age at diagnosis based on their first cancer and the 
cancer type only for their most recent cancer, respondents with more than one cancer were 
excluded. For the remaining respondents with a single cancer diagnosis, the years since 
diagnosis of breast cancer were calculated as the difference between the age at diagnosis and 
the respondent’s current age. Dummy variables were created to indicate individuals 
diagnosed with breast cancer 0–1 (index category); 2–4; 5–10; and >10 years ago. The 
American Cancer Society uses 5-year categories when they report cancer prevalence by 
years since diagnosis.30 To account for differences in HSU during the treatment phase in the 
first year after diagnosis, the authors divided the initial category (<5 years) into two 
categories (0–1 year and 2–4 years). Finally, each respondent’s race/ethnicity was classified 
as white, black, Hispanic, and other. The other category included respondents identified as 
multiracial, Asian, Native Hawaiian or other Pacific Islander, American Indian or Alaska 
Native, and other race.
The 2009 and 2010 BRFSS sample contains a total of 539,634 respondents with and without 
a history of cancer. This study excluded men, women with other cancers to enable a 
comparison of women with breast cancer to women without cancer, and respondents with 
missing values for any variable used in the analysis, resulting in a final analytic sample of 
200,268.
Estimating Health State Utility
To derive preference-based HSU values using Healthy Days, this study used Jia and 
Lubetkin’s31 mapping. Jia and Lubetkin estimated the cumulative distributions of overall 
healthy days from the 2000–2002 BRFSS and the EQ-5D scores from the 2000–2002 U.S. 
Medical Expenditure Panel Survey. The cumulative distribution shows the percentage of the 
population whose scores were less than or equal to a given value. The two cumulative 
distributions were merged by matching their percentiles. For example, if 35% of U.S. adults 
reported having ≤25 overall healthy days in the past 30, a healthy day value of 25 would be 
matched with the EQ-5D score that was the 35th percentile of the EQ-5D distribution, which 
here turns out to be 0.815. Jia and Lubetkin merged the cumulative distributions separately 
for five age categories (18–24, 25–44, 45–64, 65–74, and ≥75 years). This study mapped the 
cumulative distribution of overall healthy days in the 2009–2010 BRFSS to EQ-5D-based 
Trogdon et al. Page 3
Am J Prev Med. Author manuscript; available in PMC 2018 March 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
HSU using their crosswalk (Figure 1). The mapping assumes that the Healthy Days 
measures correspond well to the range of health states described by the EQ-5D, for which 
preference weights for the U.S. population exist.32 The advantage of this particular mapping, 
relative to one other available approach,33 is that it predicts HSUs for all ages of adults in 
the BRFSS.
Statistical Analysis
To examine means and proportions of continuous and categorical variables by age at 
diagnosis (<45 years, ≥45 years) for unadjusted differences by breast cancer status, t- and 
chi-square tests, respectively, were used. Next, linear regression (Stata, version 14.0) with 
robust variance adjustment was used to regress the mapped EQ-5D index scores on breast 
cancer, time since breast cancer diagnosis dummies (0–1 year [ref], 2–4 years, 5–10 years, 
>10 years), and the following covariates: indicators for chronic disease (diabetes, asthma, 
cardiovascular disease, stroke); education (less than high school graduate); race/ethnicity 
(for the pooled sample only, Hispanic, black, and other race); age; age squared; household 
income (<$35,000/year); currently married; smoking status (smokes some days, smokes 
every day); BMI; BMI squared; and a survey year indicator. Thus, the regressions included 
women with breast cancer and their controls. Regressions were run separately by age at 
diagnosis (<45 years, ≥45 years) and race/ethnicity (pooled races/ethnicities, white, black, 
and Hispanic). Because the estimation sample included a subset of states in 2010 and our 
primary population of interest (younger women with breast cancer) is a small subset of the 
population, this study did not use the BRFSS survey weights, which were not designed to be 
representative of the target population. All statistical tests were two-sided; this paper reports 
statistical significance at the 95% and 99% confidence levels.
Sensitivity Analysis
The authors conducted several sensitivity analyses. First, the main analysis was repeated 
separately using physically healthy days, mentally healthy days, and overall healthy days as 
the dependent variables. For these analyses, unhealthy days were converted to healthy days 
by subtracting the number of unhealthy days from 30. Second, propensity score matching 
was used prior to regression to balance the differences in observed variables between women 
with and without a history of breast cancer. Five to one nearest-neighbor propensity score 
matching with replacement was used to match women with breast cancer to statistically 
similar women without breast cancer. The propensity score was estimated using logistic 
regression with the same covariates as the regression model. The match was executed on a 
pooled sample of all races/ethnicities and then separately for each race/ethnicity group. After 
the match, no women were outside the common support of the propensity score (i.e., the 
range of propensity scores among women with breast cancer and their matched controls was 
similar). Covariate balance was checked between women with breast cancer and their 
matched women without cancer. After matching, any unbalanced covariates (p<0.1) were 
included as covariates in regression analysis. Results for all sensitivity analyses are available 
in the Appendix (available online).
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Results
Only 3.7% of the sample reported being diagnosed with breast cancer, and the mean number 
of years since breast cancer diagnosis among these women was 10.8 years (Table 1). Slightly 
less than one fifth (18.7%) of women with breast cancer were diagnosed between age 18 and 
44 years, and 81.3% were diagnosed at age ≥45 years. Comparing women with breast cancer 
with women without cancer, the former had significantly lower unadjusted mapped HSU 
(0.793 vs 0.843); mean physically healthy days (24.2 vs 26.0); and overall healthy days 
(22.1 vs 23.2). However, mean mentally healthy days (26.6 vs 26.2) were statistically 
significantly higher among women with breast cancer than among women without cancer. 
Additionally, there were statistically significant differences in comorbidities, age, education, 
race/ethnicity, household income, smoking, and BMI between women with and without 
breast cancer.
Unadjusted mean mapped utility was 0.037 lower (p<0.01) among women of all races/
ethnicities diagnosed with breast cancer between age 18 and 44 years than among women 
without cancer (0.802 vs 0.839) (Table 2). This trend was consistent across all Healthy Days 
measures (Appendix Table 1, available online). HSU differences were also significant for 
white and Hispanic women (p<0.01). Comparing women of all races/ethnicities diagnosed 
with breast cancer at age ≥45 years with women without cancer, unadjusted mean utility was 
0.049 lower (p<0.01) in the breast cancer group (0.790 vs 0.839). This trend was consistent 
across all Healthy Days measures except mentally healthy days (Appendix Table 1, available 
online). The HSU difference was also significant for women in each race/ethnicity group 
diagnosed at age ≥45 years (p<0.01).
After adjusting for covariates with multivariate regression, the HSU decrement between 
women with breast cancer and women without cancer for the younger age-at-diagnosis 
stratification was largest within 1 year of diagnosis (−0.116, p<0.01) and decreased, but was 
still significant, as years since diagnosis increased (Table 3). Similar analysis of the older 
age-at-diagnosis stratification showed the largest estimated effect on HSU within 1 year of 
diagnosis (−0.070, p<0.01) and smaller but still significant effects for each of the “years 
since diagnosis” categories. The HSU decrement associated with breast cancer within 1 year 
of diagnosis was significantly larger for women diagnosed before age 45 years (−0.116 vs 
−0.070, p<0.05). The full regressions are available in Appendix Table 2 (available online). 
Multivariate regression results using the Healthy Days measures were similar to those using 
HSU (Appendix Table 3, available online).
The HSU decrement between white women with breast cancer and white women without 
breast cancer was largest within 1 year of diagnosis (−0.126 for younger and −0.072 for 
older women, p<0.01), and smaller but still significant ≥2 years after diagnosis (Table 3). 
The HSU decrements associated with breast cancer within 1 year of diagnosis and 5–10 
years since diagnosis were significantly larger for white women diagnosed at a younger age 
compared with white women diagnosed at an older age (p<0.05).
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Among black women in the younger age-at-diagnosis group, none of the HSU decrements 
were significant. The HSU decrement within 1 year of diagnosis was significant among 
black women in the older age-at-diagnosis group (−0.051, p<0.05).
Among Hispanic women in the younger age-at-diagnosis group, the largest HSU decrement 
was for those with breast cancer at 2–4 years after diagnosis (−0.221, p<0.01), which was 
significantly larger than the similar decrement for Hispanic women diagnosed at age ≥45 
years (−0.058). The HSU decrements within the first year and 2–4 years after diagnosis were 
significant among Hispanic women in the older age-at-diagnosis group (−0.063, p<0.05, and 
−0.058, p<0.05, respectively).
Discussion
This analysis generated three key findings. First, the HRQoL effects of breast cancer are 
larger among women diagnosed at younger ages. Second, the HRQoL effects of breast 
cancer are concentrated in the first year after diagnosis, with larger effects among women 
diagnosed at younger ages. Third, there are significant differences in the HRQoL effects of 
breast cancer by race/ethnicity.
Although the HSU decrements were largest in the year after diagnosis, breast cancer can 
have long-term effects on HRQoL regardless of the age at diagnosis. The estimated HSU 
decrements were small but statistically significant at 0–1, 2–4, 5–10, and >10 years after 
diagnosis for both age-at-diagnosis groups (Table 3, first panel). Previous studies of the 
EQ-5D instrument, including one focused on cancer, have shown minimally important 
differences of 0.06–0.07.34,35 The present estimated HSU decrements were smaller than 
those used in existing decision analysis models based on older populations.36 Previous 
studies have found no long-term negative HRQoL effects among most breast cancer 
survivors, except in women with recurrence or a history of chemotherapy.37
Consistent with prior literature on HRQoL, pooled across all races/ethnicities, the effect of 
breast cancer on HSU within 1 year of diagnosis was significantly larger on younger age-at-
diagnosis women than on older age-at-diagnosis women.38–42 Relative to the minimally 
important difference thresholds of 0.06–0.07, the breast cancer decrements in the first year 
after diagnosis and the differences in those decrements between younger and older ages at 
diagnosis are clinically meaningful. The two age-at-diagnosis groups were also significantly 
different at 5–10 years after breast cancer diagnosis in the pooled data, but the decrements 
and difference in decrements were much smaller than in the first year after diagnosis. Thus, 
the larger HRQoL effects of breast cancer among women diagnosed at younger ages may be 
specific to the first year after diagnosis, during active treatment.
For black women diagnosed at a younger age, the HSU change at 2–4 years after diagnosis 
was significantly higher than for women diagnosed at an older age. This could be because 
the sample of survivors did not include those who died earlier, leaving a relatively healthier 
subset of women in the analysis. African Americans have the lowest breast cancer survival 
rate of any racial/ethnic group: 77% versus 90% among white women. African Americans 
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have reported lower breast cancer HRQoL decrements, especially in the emotional and 
mental health domains.14,23,25,41
The breast cancer decrement at 2–4 years after diagnosis for Hispanic women diagnosed 
between age 18 and 44 years was more than four times larger than the comparable 
decrement in the pooled sample and was significantly different from the comparable 
decrement for all other racial/ethnic groups. This is consistent with prior research.22–24 
Many Hispanic women face unique difficulties after breast cancer diagnosis (e.g., challenges 
navigating the U.S. medical system, occupations requiring manual labor that are difficult to 
return to post-surgery, worries about recurrence).43–47 It follows that lower acculturated 
Hispanics may be at higher risk for poorer HRQoL from a breast cancer diagnosis.14,45,48 
Hispanics are also more likely to be diagnosed with late-stage breast cancer than non-
Hispanic whites, which would lower HRQoL.49–51
Limitations
This study is subject to a number of limitations. BRFSS is limited to the non-
institutionalized population, and self-reports of cancer and low response rates could have 
resulted in a non-representative sample of respondents. BRFSS also had few breast cancer 
diagnoses at younger ages among black (n=136) and Hispanic (n=69) women, which limited 
the power to detect differences by race/ethnicity. Race/ethnicity is culturally complex and it 
is difficult to separate the effects of race/ethnicity from other concepts like SES. Because 
respondents were asked to report age at diagnosis based on their first cancer and only 
reported cancer type for their most recent cancer, individuals with multiple cancers were 
excluded from the analysis. BRFSS did not provide data on breast cancer stage, recurrence, 
or treatment. Differences in the types of cancers and treatment received by younger women 
could be driving the differences by age. However, the authors cannot test that hypothesis in 
these data. The authors believe a contribution of this paper is to generate these types of 
hypotheses by describing the differences in HSU by age at diagnosis. Finally, the mapping 
of Jia and Lubetkin31 adds additional uncertainty to the estimates, which are also subject to 
the limitations of the original mapping (e.g., mapping across two different data sets, overlap 
across physically and mentally unhealthy days).
Conclusions
The effect of breast cancer on HRQoL varies by age at diagnosis, time since diagnosis, and 
race/ethnicity. The results suggest that separate QoL adjustments for women by age at 
diagnosis and race/ethnicity would be important for conducting cost-effectiveness analysis 
of breast cancer prevention, detection, and treatment. This study provides HSU estimates for 
younger women with breast cancer by race/ethnicity that can be used to model downstream 
health states in secondary or observational models. However, the authors acknowledge that 
concerns about equity and fairness could arise if minorities experienced lower HSU 
decrements from breast cancer, which could lead to higher incremental cost-effectiveness 
ratios for interventions targeted at these groups. In the results, Hispanic women experienced 
higher, not lower, HSU decrements; the estimates for black women were generally 
imprecisely estimated. Breast cancer diagnosed in women younger than age 45 years may 
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place a greater burden on their QoL than in older women, especially among younger 
Hispanic women.
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Figure 1. 
Converting healthy days to health state utility scores.
BRFSS, Behavioral Risk Factor Surveillance System; EQ-5D, EuroQoL five-dimensions; 
HSU, health state utility; MEPS, Medical Expenditure Panel Survey.
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Table 1
BRFSS Descriptive Statistics for All Races/Ethnicities
Variable Breast cancer (n=7,426) No cancer (n=192,842)
Diagnosed with
 Breast cancer at age (years)
  18–44 18.7 N/A
  ≥45 81.3 N/A
 Diabetes 15.1 10.1
 Asthma 9.4 10.2
 Cardiovascular disease 7.2 4.0
 Stroke 5.0 3.1
Years since breast cancer diagnosis, M (SD)a 10.8 (9.6) N/A
Age at breast cancer diagnosis 55.8 (12.5) N/A
Mapped health state utility (0.0–1.0), M (SD) 0.793 (0.181) 0.843 (0.170)
Healthy days (HRQoL-4)
 Physically healthy days, M (SD) 24.2 (9.9) 26.0 (8.3)
 Mentally healthy days, M (SD) 26.6 (7.6) 26.2 (7.9)
 Days without activity limitations, M (SD) 26.9 (7.6) 27.6 (6.7)
 Overall healthy days, M (SD)b 22.1 (11.1) 23.2 (10.2)
Age, M 66.5 53.5 (16.0)
Education (less than high school graduate) 6.5 7.7
Race/ethnicity
 White, non-Hispanic 85.1 77.7
 African American, non-Hispanic 6.6 9.3
 Hispanic, any race 3.7 7.3
 Other, non-Hispanicc 4.6 5.7
Household income <$35,000/year 49.0 42.7
Currently married 45.8 54.1
Smokes some days 3.4 4.4
Smokes every day 7.3 12.0
BMI, M (SD) 27.2 (5.7) 27.6 (6.4)
2009 BRFSS 87.7 86.5
Note: Values are percentages unless otherwise noted. All differences between women with and without breast cancer are statistically significant 
(p<0.05).
a
Years since diagnosis for women with a breast cancer diagnosis.
bOverall healthy days = 30 – (physically unhealthy days) – (mentally unhealthy days); values <0 are set to 0. This measure is used in the health 
state utility value from Jia and Lubetkin.34
cNon-Hispanic Asian, American Indian, Pacific Islander, other race, or multiracial.
BRFSS, Behavioral Risk Factor Surveillance System; HRQoL, health-related quality of life; N/A, not applicable.
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